255893-33-5

Upstream product

• 367-30-6 2,5-difluoroaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 110-85-0 piperazine 
• 367-23-7 1,2,4-trifluorobenzene 

Downstream Products

• 1355156-02-3 2-{3-(4-chlorobenzoyl)-4-[(4-(2,5-difluorophenyl)piperazin-1-yl)methyl]thiophen-2-yl}-isoindole-1,3-dione 
• 1027492-81-4 {2-amino-4-[(4-(2,5-difluorophenyl)piperazin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone 
• 1355156-50-1 2-{5-bromo-3-(4-chlorobenzoyl)-4-[(4-(2,5-difluorophenyl)piperazin-1-yl)methyl]thiophen-2-yl}-isoindole-1,3-dione 
• 1239668-14-4 C₂₀H₂₀F₂N₂O 
• 946522-92-5 tert-butyl ester of {2-[4-(2,5-difluorophenyl)piperazin-1-yl]-2-oxoethyl}carbamic acid 

Relevant academic research and scientific papers

Microwave-assisted amination from fluorobenzenes without catalyst and strong base

A facile and versatile amination of fluorobenzenes has been developed in good to excellent yields under microwave irradiation in N-methylpyrrolidinone (NMP) without strong base and catalyst. The presence of additional halogen atom(s) enhanced the leaving ability of fluorine and meta fluorine gave higher activation than the ortho. It is remarkable that 1,2,3-trifluorobenzene, 1,2,4-trifluorobenzene and 1,2,4,5-tetrafluorobenzene can produce the regioselective mono-substituted products.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.

Compounds specific for the human alpha1d adrenergic receptor and uses thereof

This invention is directed towards a method of inhibiting activation of a human α1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human ald adrenergic receptor. This invention provides for a compound which binds selectively to a human α1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human α1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.